Prof. Dr. Bernhard Küster

Academic Career and Research Areas

Professor Küster (b. 1967) conducts research in the field of chemical and functional proteomics. This research focuses on a range of questions relating to how proteins interact with each other and with active pharmaceutical ingredients, which molecular mechanisms play a role in cancer and how these can be used for individual approaches to clinical treatment. He uses chemical and biochemical methods as well as spectroscopic and bioinformatic high throughput technologies.

After studying chemistry at the University of Cologne, Professor Küster obtained his doctorate in biochemistry at the University of Oxford. He subsequently worked as a postdoctoral researcher in Heidelberg, Germany, and Odense, Denmark. Prior to becoming a full professor at TUM and until 2007 he was Vice President of Cellzome AG, a Heidelberg-based biotech company. Professor Küster is the Chair of the TUM Department of Biosciences and a member of the Graduate School Experimental Medicine. His research is funded by the Center for integrated Protein Science Munich (CiPSM), the German Consortium for Translational Cancer Research (DKTK) and the pharmaceutical industry. Professor Küster is one of the founders of the biotech company OmicScouts GmbH.


  • Carl von Linde Senior Fellow, TUM Institute for Advanced Study (2018)
  • Discovery in Proteomic Sciences Award, Human Proteome Organization (2015)
  • Heinz Maier-Leibnitz Medal, TUM (2014)
  • Long-term fellow, European Molecular Biology Organization (1998)
  • Mattauch-Herzog Award, German Mass Spectrometry Society (1998)

Key Publications (alle Publikationen)

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Re Depaolini S, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner P, Hahne H, Tonisson N, Kramer K, Goetze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif P, Schneider S, Felder ER, Ruland J, Medard G, Jeremias I, Spiekermann K, Kuster B: „The target landscape of clinical kinase drugs“. Science. 2917; 358: pii: eaan4368


Zolg DP, Wilhelm M, Schnatbaum K, Zerweck J, Knaute T, Delanghe B, Bailey DJ, Gessulat S, Ehrlich HC, Weininger M, Yu Y, Schlegl J, Kramer K, Schmidt T, Kusebauch U, Deutsch EW, Aebersold R, Moritz RL, Wenschuh H, Moehring T, Aiche S, Huhmer A, Reimer U, Kuster B: “Building Proteometools based on a complete synthetic human proteome”. Nature Methods. 2017; 14: 259-262.


Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese JH, Bantscheff M, Gerstmair A, Faerber F, Kuster B: „Mass spectrometry based draft of the human proteome“. Nature. 2014; 509: 582-587.


Marx H, Lemeer S, Schliep JE, Matheron L, Mohammed S, Cox J, Mann M, Heck AJR, Kuster B: “A large synthetic peptide and phosphopeptide library for mass spectrometry– based proteomics”. Nat Biotechnol. 2013; 31: 557-564.


Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V, Sweetman G, Bauer A, Bouwmeester T, Hopf C, Kruse U, Neubauer G, Ramsden N, Rick J, Kuster B, Drewes G: “Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors“. Nat. Biotechnol. 2007; 25: 1035-1044.